European Union Clinical Trials Regulation Came into Effect
Biden reignites the Cancer Moonshot, setting ambitious goals: to reduce the death rate from cancer by at least 50 percent over the next 25 years
International Cancer Coalition Launch
In 2021, the International Cancer Coalition officially launched at the Bloomberg New Economy Forum in Singapore.
Forbes China Healthcare Summit opens the door to “Ping-Pong Diplomacy of the 21st Century”
The 2021 Forbes China Healthcare Summit was held to discuss the theme of “Advance the Global Fight Against Cancer and Achieve a Moonshot in the Post-Pandemic Era.”
FDA granted accelerated approval to sotorasib (Lumakras)
A pandemic-era CodeBreaK100 international trial led to FDA accelerated approval of sotorasib (Lumakras), the first targeted drug against KRAS, the commonest oncogene driver in human cancers which was previously thought to be uncurable.
Bloomberg New Economy Forum hosted Moonshot Roundtable
The Bloomberg New Economy Forum convened a special “Moonshot Roundtable” gathering CEOs from major global biopharmaceuticals, leading academic physicians, and top government regulators including FDA’s Oncology Center of Excellence.
Forbes China Healthcare Summit launched
Forbes China Healthcare Summit launched, bringing together leading academic, industry, and government stakeholders in the U.S. and China to collaborate on international clinical trials in the COVID-19 pandemic era.
Bloomberg New Economy Forum
Bloomberg New Economy Forum in Beijing convened the first U.S.-China Task Force and recommended multi-stakeholder collaboration on international cancer clinical trials.
FDA initiates Project Orbis
The U.S. FDA initiated Project Orbis to provide a framework for the submission and review of oncology products among international government regulatory agencies, with Australia and Canada as the first...
Asia Society, MSK, and CTONG Join Forces
Asia Society, MSK, and CTONG join forces to establish a platform to advance U.S.-China and international cancer trials to fight the common enemy.